Silence Therapeutics plc
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
8. Benefit from R&D credit
An addi tional $2.4 million was recognized in respect of research and development tax credits in the three months ended June 30, 2025 (three months ended June 30, 2024: $2.7 million).
An additional $5.1 million was recognizedin respect of research and development tax credits in the six months ended June 30, 2025 (six months ended June 30, 2024: $5.2 million).
The current assets at June 30, 2025, was $20.0 million, comprised of $5.1 million in respect of research and development activities for the six months ended June 30, 2025, and $14.9 million in respect of the year ended December 31, 2024. In the six months ended, June 30, 2025, the Group received $11.0 million related to the receipt of the 2023 claim for past research and development tax credits.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.